Zydus Cadila proposes Rs 1,900 for 3 jabs of DNA-based vaccine

With talks underway between the central government and Zydus Cadila over the pricing of the COVID-19 vaccine ZyCov-D, the pharma company is learnt to have proposed a price of Rs 1,900 for its......

India imposes tit-for-tat Covid curbs on UK nationals

British nationals arriving in India, irrespective of their vaccination status, will have to undergo 10 days of mandatory quarantine from October 4 as part of the reciprocal actions initiated by the......

Russia reaches out to Kerala for Sputnik V plant

The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms......

Zydus Cadila to begin vaccine trials for kids above 5 yrs soon

So far, no other vaccine has been approved globally for children below 12 years.Sohini Das reports.  IMAGE: A beneficiary receives a dose of the Covid-19 vaccine at a vaccination centre in......

Budget 2023: What the pharma, healthcare industry seek

The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Illustration:......

Key mantra for India's pharma sector in 2023

Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of......

Reports of coal crisis baseless: Sitharaman

Amid reports of the ongoing coal shortage in the country, Finance Minister Nirmala Sitharaman stressed that there is no shortage and termed these as “absolutely baseless”, saying India......

Lupin aims to enter Chinese market in the next one year

Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time. Mumbai-headquartered Lupin is firming up plans to......